212 related articles for article (PubMed ID: 10943907)
21. Acamprosate: recent findings and future research directions.
Mann K; Kiefer F; Spanagel R; Littleton J
Alcohol Clin Exp Res; 2008 Jul; 32(7):1105-10. PubMed ID: 18540918
[TBL] [Abstract][Full Text] [Related]
22. The mosaic of addiction.
O'Brien CP
Am J Psychiatry; 2004 Oct; 161(10):1741-2. PubMed ID: 15465965
[No Abstract] [Full Text] [Related]
23. Pharmacologic approaches to the management of alcoholism.
Anton RF
J Clin Psychiatry; 2001; 62 Suppl 20():11-7. PubMed ID: 11584870
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
Boening JA; Lesch OM; Spanagel R; Wolffgramm J; Narita M; Sinclair D; Mason BJ; Wiesbeck GA
Alcohol Clin Exp Res; 2001 May; 25(5 Suppl ISBRA):127S-131S. PubMed ID: 11391061
[TBL] [Abstract][Full Text] [Related]
25. The clinical pharmacology of acamprosate.
Kalk NJ; Lingford-Hughes AR
Br J Clin Pharmacol; 2014 Feb; 77(2):315-23. PubMed ID: 23278595
[TBL] [Abstract][Full Text] [Related]
26. Acamprosate does not induce a conditioned place preference and reveals no state-dependent effects in this paradigm.
Kratzer U; Schmidt WJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):653-6. PubMed ID: 12787853
[TBL] [Abstract][Full Text] [Related]
27. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats.
Kotlinska J; Bochenski M
Eur J Pharmacol; 2008 Nov; 598(1-3):57-63. PubMed ID: 18838071
[TBL] [Abstract][Full Text] [Related]
28. [Alcohol--mechanism of action, interactions and treatment of alcohol abuse].
Korpi E; Seppälä T
Duodecim; 1998; 114(10):1029-36. PubMed ID: 11524777
[No Abstract] [Full Text] [Related]
29. New pharmacological approaches for the treatment of alcoholism.
Soyka M; Roesner S
Expert Opin Pharmacother; 2006 Dec; 7(17):2341-53. PubMed ID: 17109610
[TBL] [Abstract][Full Text] [Related]
30. Acamprosate produces its anti-relapse effects via calcium.
Spanagel R; Vengeliene V; Jandeleit B; Fischer WN; Grindstaff K; Zhang X; Gallop MA; Krstew EV; Lawrence AJ; Kiefer F
Neuropsychopharmacology; 2014 Mar; 39(4):783-91. PubMed ID: 24081303
[TBL] [Abstract][Full Text] [Related]
31. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study.
Tempesta E; Janiri L; Bignamini A; Chabac S; Potgieter A
Alcohol Alcohol; 2000; 35(2):202-9. PubMed ID: 10787398
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence.
Boeijinga PH; Parot P; Soufflet L; Landron F; Danel T; Gendre I; Muzet M; Demazières A; Luthringer R
Neuropsychobiology; 2004; 50(1):71-7. PubMed ID: 15179024
[TBL] [Abstract][Full Text] [Related]
33. Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference.
Kiefer F; Jahn H; Otte C; Nakovics H; Wiedemann K
Neurosci Lett; 2006 Aug; 404(1-2):103-6. PubMed ID: 16782270
[TBL] [Abstract][Full Text] [Related]
34. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat.
Spanagel R; Hölter SM; Allingham K; Landgraf R; Zieglgänsberger W
Eur J Pharmacol; 1996 Jun; 305(1-3):39-44. PubMed ID: 8813529
[TBL] [Abstract][Full Text] [Related]
35. Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference.
Zalewska-Kaszubska J; Górska D; Dyr W; Czarnecka E
Neurosci Lett; 2008 Feb; 431(3):221-5. PubMed ID: 18162308
[TBL] [Abstract][Full Text] [Related]
36. The effect of acamprosate on the development of morphine-induced behavioral sensitization in rats.
Kratzer U; Spanagel R; Schmidt WJ
Behav Pharmacol; 2003 Jul; 14(4):351-6. PubMed ID: 12838041
[TBL] [Abstract][Full Text] [Related]
37. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.
Cowen MS; Adams C; Kraehenbuehl T; Vengeliene V; Lawrence AJ
Addict Biol; 2005 Sep; 10(3):233-42. PubMed ID: 16109584
[TBL] [Abstract][Full Text] [Related]
38. [Acamprosate and naltrexone: similar efficacy for relapse].
Saitz R
Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
[No Abstract] [Full Text] [Related]
39. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Kiefer F; Helwig H; Tarnaske T; Otte C; Jahn H; Wiedemann K
Eur Addict Res; 2005; 11(2):83-91. PubMed ID: 15785069
[TBL] [Abstract][Full Text] [Related]
40. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
Schmidt LG; Smolka MN
Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
